The Corona Remedies IPO is one of the most anticipated pharma IPO launches in the Indian pharmaceutical market (IPM). As a fast-growing branded pharmaceutical formulation company, Corona Remedies Limited is preparing to list on the mainboard, offering retail investors an opportunity to participate in a business that has consistently delivered growth across multiple therapeutic areas including women’s healthcare, cardio-diabeto, urology, and pain management.
With strong domestic sales, two modern manufacturing facilities, and a robust distribution network, this Corona Remedies Limited IPO is drawing significant attention.
Corona Remedies IPO Details
| Detail | Information |
|---|---|
| IPO Date | December 8, 2025, to December 10, 2025 |
| Face Value | ₹10 per share |
| Issue Price Band | ₹1008 to ₹1062 per share |
| Lot Size | 14 Shares |
| Total Issue Size | ₹655.37 Cr (Offer for Sale) |
| Issue Type | Bookbuilding IPO |
| Sale Type | Offer For Sale |
| Listing At | BSE, NSE |
| Share Holding Pre-Issue | 6,11,60,088 shares |
| Share Holding Post-Issue | 6,11,60,088 shares |
Corona Remedies IPO Timeline
| Event | Date |
|---|---|
| IPO Open Date | Mon, Dec 8, 2025 |
| IPO Close Date | Wed, Dec 10, 2025 |
| Basis of Allotment | Thu, Dec 11, 2025 |
| Initiation of Refunds | Fri, Dec 12, 2025 |
| Credit of Shares to Demat | Fri, Dec 12, 2025 |
| IPO Listing Date | Mon, Dec 15, 2025 |
| UPI Mandate Cut-off | 5 PM on Wed, Dec 10, 2025 |
Company Overview: Corona Remedies Limited
Corona Remedies Ltd is a pharmaceutical company focused on developing, manufacturing, and marketing branded formulations across high-growth therapeutic segments. Established with a strategic focus on multispecialty pharmaceuticals, the company has built strong recognition among healthcare professionals and deep penetration across the Indian pharmaceutical market.
The company operates out of Corona House, Mondeal Business Park, and is backed by years of demonstrated capabilities in formulation development, marketing, and pan-India distribution.
Key highlights:
Among the fastest growing companies in the IPM
Strong presence in women’s healthcare, cardio-diabeto, pain management, and niche therapeutic segments
Trusted by healthcare professionals for its branded, high-quality pharmaceutical offerings
Two modern manufacturing facilities supporting growing domestic sales
Business Overview
The company operates across several therapeutic areas, catering to the needs of millions through targeted product portfolios. Its business model revolves around:
1. Branded Pharmaceutical Formulations
Corona Remedies is recognized as a pharmaceutical company developing high-quality branded formulations. Its products span:
Women’s healthcare
Cardio-diabeto
Pain management & urology
Dermatology & gastrointestinal health
2. Strong Pan-India Distribution
The company ensures deep penetration through:
A wide network of distributors
Pan-India field force
Local & regional reach in key Indian market clusters
3. Manufacturing Capability
It operates two manufacturing facilities equipped to support volume growth and meet the demands of high-potential therapeutic lines.
4. Focus on Engagement with Healthcare Professionals
Through effective engagement strategies, CRM systems, and medical activities, the company ensures strong recall and consistent prescription growth.
Financial Performance (Restated Consolidated)
Corona Remedies Ltd.'s financial performance demonstrates strong growth:
| Metric | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,012.38 | 929.86 | 830.58 | 595.02 |
| Total Income | 348.56 | 1,202.35 | 1,020.93 | 891.10 |
| Profit After Tax | 46.20 | 149.43 | 90.50 | 84.93 |
| EBITDA | 71.80 | 245.91 | 161.19 | 135.03 |
| Net Worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Reserves & Surplus | 545.86 | 545.18 | 419.25 | 347.36 |
| Total Borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
| Amount in ₹ Crore |
Key takeaways:
Revenue grew 18% YoY in FY25
PAT rose 65% YoY, indicating strong profitability
Increasing EBITDA suggests operational efficiency
Strong balance sheet with robust reserves
Corona Remedies IPO Allotment & Listing
The Corona Remedies IPO allotment will be handled by Bigshare Services Pvt Ltd, the IPO registrar for this issue.
Retail investors can check their IPO allotment status on:
Bigshare Services Pvt Ltd website
BSE IPO allotment page
Through their broker or demat account
Expected listing:
IPO Listing Date: December 15, 2025
The company will list on both BSE and NSE
How to Apply for Corona Remedies IPO
You can apply for Corona Remedies IPO using:
UPI-based applications via broker apps
Net banking ASBA through your bank account
Requirements:
Valid demat account
Linked bank account
UPI ID (for retail investors)
Steps:
Log in to your trading app (Zerodha, Groww, Tradejini, etc.)
Search for Corona Remedies IPO
Enter lot size (minimum 14 shares)
Approve UPI mandate
Track allotment status after close date
Conclusion
The Corona Remedies IPO offers exposure to a fast-growing branded pharmaceutical company with strong domestic sales, diversified therapeutic segments, and a solid financial track record. With a well-established distribution network and increasing profitability, it stands out in the Indian pharmaceutical market.
Retail investors looking for long-term exposure to the expanding pharma sector may find this IPO worth evaluating—while also reviewing risks associated with the company’s growth trajectory and sector competition.
Disclaimer: The information provided in our blogs is for informational purposes only and should not be construed as financial, investment, or trading advice. Trading and investing in the securities market carries risk. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. Copyrighted and original content for your trading and investing needs.
© 2025 — Tradejini. All Rights Reserved.
